News
News
- Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients
09/27/2017 / 07:30 - GlobeNewswire - Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414
08/31/2017 / 23:15 - GlobeNewswire - Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MOR209/ES414
12/15/2016 / 19:55 - GlobeNewswire - MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor
12/13/2016 / 07:38 - GlobeNewswire - MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor
12/13/2016 / 07:30 - GlobeNewswire - MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
12/06/2016 / 07:42 - GlobeNewswire - MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference
12/06/2016 / 07:40 - GlobeNewswire - MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference:
12/06/2016 / 07:30 - GlobeNewswire - MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
12/06/2016 / 07:30 - GlobeNewswire - MorphoSys AG: Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) with the aim of pan-European distribution
11/29/2016 / 16:00 - GlobeNewswire
Real-time